Clinical Trials Logo

Oncology clinical trials

View clinical trials related to Oncology.

Filter by:

NCT ID: NCT00807859 Completed - Breast Cancer Clinical Trials

Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer

Start date: March 9, 2009
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine if AMG 386 in combination with either paclitaxel and trastuzumab or capecitabine and lapatinib is safe and well tolerated in subjects with HER2-positive locally recurrent or metastatic breast cancer. This is an open-label phase 1b trial and has 2 study parts. Study part 1 is a dose escalation study to determine a tolerable dose of AMG 386 in combination with paclitaxel and trastuzumab (cohort A) or with capecitabine and lapatinib (cohort B). Study part 2 is cohort expansion of the tolerable doses determined in part 1.

NCT ID: NCT00770536 Completed - Cancer Clinical Trials

AMG386 Comb w. Either Pegylated Liposomal Doxorubicin or Topotecan Subjects w. Advanced Recurrent Epithelial Ovarian CR

Start date: January 2009
Phase: Phase 1
Study type: Interventional

This study is a 2 part, 2 cohort, open-label, dose escalation/de escalation study of AMG 386 in combination with either pegylated liposomal doxorubicin or topotecan in subjects with recurrent ovarian cancer. Up to 100 subjects will be enrolled to receive AMG 386 in combination with either pegylated liposomal doxorubicin every 4 weeks (cohort A) or topotecan weekly on days 1, 8, and 15 of a 28 day dosing schedule (cohort B). Subject enrollment and assignment to either cohort will be based on eligibility and the investigator's discretion. It is hypothesized that AMG 386, in combination with each of the chemotherapy regimens: either pegylated liposomal doxorubicin or topotecan will be safe and well tolerated in subjects with recurrent ovarian cancer.

NCT ID: NCT00752570 Completed - Cancer Clinical Trials

A Phase 2, Randomized, Double Blind, Placebo Controlled Study of AMG 386 in Combination With FOLFIRI in Subjects With Previously Treated Metastatic Colorectal Carcinoma

Start date: November 2008
Phase: Phase 2
Study type: Interventional

This clinical trial will compare the efficacy and safety of the combination of AMG 386 and FOLFIRI with FOLFIRI alone in second line treatment of metastatic colorectal cancer.

NCT ID: NCT00630786 Completed - Colorectal Cancer Clinical Trials

Conatumumab/Panitumumab Combination Metastatic Colorectal Cancer Study

Start date: January 2008
Phase: Phase 1/Phase 2
Study type: Interventional

This is an exploratory phase 1b/2, global, multicenter, single-arm, 2-part (phase 1b and 2) study of conatumumab in combination with panitumumab in patients with Metastatic Colorectal Cancer.

NCT ID: NCT00588289 Completed - Oncology Clinical Trials

Long Term Follow-Up of Patients on Children's Cancer Group Protocols- (CCG-LTF1) FOLLOW-UP DATA

Start date: September 1999
Phase: N/A
Study type: Observational

This protocol is not an independent research study, but rather a means to aggregate Children's Cancer Group protocols that are closed to patient entry for the purpose of collecting current status information on those patients treated under those protocols.

NCT ID: NCT00547157 Completed - Cancer Clinical Trials

Radiotherapy Plus Panitumumab Compared to Chemoradiotherapy With Unresected, Locally Advanced Squamous Cell Carcinoma of the Head and Neck

Start date: November 2007
Phase: Phase 2
Study type: Interventional

The purpose of this study is to estimate, with pre-specified precision, the difference in local-regional control (LRC) rate at 2 years in subjects receiving chemoradiotherapy (CRT) or panitumumab plus radiotherapy (PRT) as first line treatment for locally advanced squamous cell carcinoma for the head and neck (SCCHN). A formal hypothesis will not be tested in this trial; however, the treatment arm difference in LRC rates at 2 years will be estimated.

NCT ID: NCT00446446 Completed - Cancer Clinical Trials

PRISM (Panitumumab Regimen In Second-line Monotherapy of Head and Neck Cancer)

Start date: October 30, 2007
Phase: Phase 2
Study type: Interventional

To estimate the effect of second-line panitumumab monotherapy on objective response in patients with metastatic or recurrent squamous cell carcinoma of head and neck (SCCHN).

NCT ID: NCT00413283 Completed - Cancer Clinical Trials

Dose/ Schedule Finding Trial of Romiplostim for Chemotherapy-Induced Thrombocytopenia (CIT) in Non-Small Cell Lung Cancer (NSCLC)

Start date: December 2006
Phase: Phase 2
Study type: Interventional

The purpose of this study is to identify an effective, well tolerated dose and schedule of romiplostim that is appropriate for the treatment of chemotherapy induced thrombocytopenia (CIT) in patients with non-small cell lung cancer receiving gemcitabine and platinum.

NCT ID: NCT00411450 Completed - Cancer Clinical Trials

Panitumumab Regimen Evaluation in Colorectal Cancer to Estimate Primary Response to Treatment

PRECEPT
Start date: November 2006
Phase: Phase 2
Study type: Interventional

The primary objective is to estimate the effect of the human homolog of the Kirsten rat sarcoma-2 virus oncogene (KRAS) mutation status (wild type versus mutant) from tumor tissue on efficacy endpoints in patients with metastatic colorectal cancer (mCRC) receiving second-line chemotherapy with panitumumab after failing first-line treatment.

NCT ID: NCT00352950 Withdrawn - Clinical trials for Non-Small Cell Lung Cancer

Safety Evaluation of Panitumumab and Sirolimus in Advanced Non-Small Cell Lung Cancer

Start date: March 2006
Phase: Phase 1
Study type: Interventional

To determine the dose and schedule of sirolimus when given in combination with panitumumab in adult subjects with Stage IIIB/IV NSCLC